The pharmaceutical company that makes the asthma drug Advair and the antidepressants Paxil and Wellbutrin will pay $105 million to Texas and 43 other states for misrepresenting the uses of its drugs.
Texas Attorney General Greg Abbott scooped up $6.2 million of that from British drug maker GlaxoSmithKline, which unlawfully promoted the medications. It’s against federal law to promote uses of pharmaceuticals not approved by the Food and Drug Administration.
California Attorney General Kamela Harris announced the settlement on Wednesday. Her state gained the most from it: $7.1 million. The judgment also led to “a major change in the way pharmaceutical sales teams are motivated and compensated,” according to a statement from Abbott’s office.
GlaxoSmithKline, the U.K.’s largest drug manufacturer, must continue its ‘Patients First’ program through 2019. That plan reduces financial incentives for its sales representatives, which is designed to reduce deceptive marketing strategies.
It also calls for “scientifically trained personnel” to “develop and approve unbiased and non-promotional responses to healthcare provider questions.” Glaxo is no stranger to fines: In 2012, it agreed to pay $3 billion for similar claims that it misrepresented drugs and failed to report safety data.
That remains the largest settlement ever reached with a pharmaceutical company.